Atrial fibrillation and stroke: From scientific evidence to practice

Clinical and Experimental Hypertension

Volumn 28, Issue 3-4, 2006, Pages 251-257

  Deplanque, Dominique ^a,b,c   Leys, Didier ^b  

^a Faculty of Medicine   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

Author keywords

Atrial fibrillation; Guidelines; Medical education; Oral anticoagulation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULATION; BRAIN HEMORRHAGE; BRAIN INJURY; CLINICAL PRACTICE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FALLING; FOLLOW UP; GAIT DISORDER; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; LEUKOARAIOSIS; LOW DRUG DOSE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TREATMENT CONTRAINDICATION; CEREBROVASCULAR ACCIDENT; PATIENT EDUCATION; PROGNOSIS; REVIEW; RISK FACTOR;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HUMANS; PATIENT EDUCATION; PRACTICE GUIDELINES; PRIMARY PREVENTION; PROGNOSIS; RISK FACTORS;

EID: 33746450465     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600549181     Document Type: Conference Paper

References (30)

1. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol 2003; 2:177-188.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155:469-473.
3. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22:312-318.
4. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiological assessment of chronic atrial fibrillation and the risk of stroke: the Framingham Study. Neurology 1978; 28:973-977.
5. Jørgensen HS, Nakayama H, Reith J, Raasschou HO, Olsen TS. Acute stroke with atrial fibrillation: the Copenhagen stroke study. Stroke 1996; 10:1765-1769.
6. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 1996; 27:1760-1764.
7. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 333:175-179.
8. Stroke Prevention in Atrial Fibrillation investigators. Predictors of thromboembolism in atrial fibrillation: Part I. Clinical features of patients at risk. Ann Intern Med 1992; 116:1-5.
9. Stroke Prevention in Atrial Fibrillation investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116:6-12.
10. Boston Area Anticoagulation Trial for Atrial Fibrillation investigators. The effects of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511.
11. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulàtion (CAFA) Study. J Am Coll Cardiol 1991; 18:349-355.
12. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation investigators. N Engl J Med 1992; 327:1406-1412.
13. Stroke Prevention in Atrial Fibrillation investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343:687-691.
14. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation investigators. Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin: stroke prevention in atrial fibrillation III study. JAMA 1998; 279:1273-1277.
15. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 51:674-681.
16. EAFT (European Atrial Fibrillation Trial) study group. European Atrial Fibrillation Trial: secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
17. Leys D, Kwiecinski H, Bogousslavky J, Bath P, Brainin M, Diener HC, et al. Recommendations of the European Stroke Initiative (EUSI): stroke prevention. Cerebrovasc Dis 2004; 17(suppl 2): 5-29.
18. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996; 124:283-291.
19. Krumholz HM, Radford MJ, Ellerbeck E, Hennen J, Meehan TP, Petrillo M, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcome. Circulation 1995; 92:2841-2847.
20. Krumholz HM, Radford MJ, Ellerbeck E, Hennen J, Meehan TP, Petrillo M, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996; 124:292-298.
21. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155:277-281.
22. Kutnner M, Nixon G, Silverstone F. Physicians attitudes toward oral anticoagulant and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151:1950-1953.
23. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156:2553-2562.
24. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28:2382-2389.
25. Kalra L, Perez I, Melbourn A. Stroke risk management. Changes in mainstream practice. Stroke 1998; 29:53-57.
26. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V and the SAFE I. Study Investigators. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? Heart 1999; 82:563-569.
27. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J, and the SAFE II investigators. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57:798-806.
28. Go AS, Hylek EM, Borowsky LH, Philips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Int Med 1999; 131:927-934.
29. Hyleck EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902.
30. Deplanque D, Leys D. Intracranial haemorrhage and long term anticoagulant therapy: which risk factors? Sang Thrombose Vaisseaux 2002; 14:255-262.